Inhibition of the CXCL12‐CXCR4 axis has resulted in increased T‐cell infiltration of PDAC tumours, and combined with checkpoint blockade, enhances pancreatic cancer therapeutic efficacy [17, 29, 30]. This evidence concerns the gene CXCR4 and pancreatic neoplasm.